Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has 3 years of Total Non-Current Liabilities data on file, last reported at $117.1 million in Q3 2021.

• Total Non-Current Liabilities for Q3 2021 came in at $117.1 million, up 13.23% year-over-year; the trailing twelve-month figure through Aug 2021 was $117.1 million (up 13.23% YoY), and the FY2020 annual result was $105.2 million, up 103.02% from the prior year.
• Total Non-Current Liabilities fell to $117.1 million in Q3 2021 per NRIX's latest filing, from $119.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $125.7 million in Q1 2021 and troughed at $51.8 million in Q4 2019.
• A 3-year average of $103.7 million and a median of $111.1 million in 2020 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2020 and 2021: Total Non-Current Liabilities jumped 103.02% in 2020, then increased 13.23% in 2021.
• A 3-year view of Total Non-Current Liabilities shows it stood at $51.8 million in 2019, then jumped by 103.02% to $105.2 million in 2020, then gained by 11.25% to $117.1 million in 2021.
• Business Quant data shows NRIX's Total Non-Current Liabilities at $117.1 million in Q3 2021, $119.0 million in Q2 2021, and $125.7 million in Q1 2021.